Regeneron Pharmaceuticals Inc (REGN) Stake Lowered by QUANTRES ASSET MANAGEMENT Ltd

Share on StockTwits

QUANTRES ASSET MANAGEMENT Ltd decreased its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 42.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,200 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. QUANTRES ASSET MANAGEMENT Ltd’s holdings in Regeneron Pharmaceuticals were worth $889,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 12.7% in the 2nd quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock worth $621,927,000 after buying an additional 203,306 shares during the last quarter. Polen Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 4.5% in the 2nd quarter. Polen Capital Management LLC now owns 1,483,634 shares of the biopharmaceutical company’s stock worth $511,839,000 after buying an additional 64,493 shares during the last quarter. Northern Trust Corp lifted its position in Regeneron Pharmaceuticals by 2.0% in the 2nd quarter. Northern Trust Corp now owns 934,245 shares of the biopharmaceutical company’s stock worth $322,306,000 after buying an additional 17,931 shares during the last quarter. Manning & Napier Group LLC lifted its position in Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Manning & Napier Group LLC now owns 516,338 shares of the biopharmaceutical company’s stock worth $178,130,000 after buying an additional 23,315 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in Regeneron Pharmaceuticals by 53.5% in the 3rd quarter. First Trust Advisors LP now owns 288,480 shares of the biopharmaceutical company’s stock worth $116,557,000 after buying an additional 100,492 shares during the last quarter. 65.95% of the stock is owned by institutional investors.

In other news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael S. Brown sold 2,000 shares of the stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total value of $784,520.00. Following the completion of the sale, the director now directly owns 2,000 shares in the company, valued at $784,520. The disclosure for this sale can be found here. Over the last three months, insiders sold 112,052 shares of company stock worth $45,411,762. Insiders own 12.42% of the company’s stock.

A number of analysts recently weighed in on REGN shares. SunTrust Banks set a $344.00 target price on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 2nd. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Friday, July 13th. Finally, Argus boosted their price objective on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research report on Monday, July 16th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $410.95.

NASDAQ REGN opened at $336.18 on Tuesday. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $432.50. The firm has a market capitalization of $36.29 billion, a PE ratio of 25.07, a P/E/G ratio of 1.13 and a beta of 1.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, topping analysts’ consensus estimates of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The firm had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the prior year, the firm posted $4.17 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.31 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: What is a put option?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply